Deep learning model with collage images for the segmentation of dedicated breast positron emission tomography images
CONCLUSIONS: Deep learning can be applied for the automatic segmentation of dbPET, and collage images can improve model performance.PMID:37634221 | DOI:10.1007/s12282-023-01492-z (Source: Breast Cancer)
Source: Breast Cancer - August 27, 2023 Category: Cancer & Oncology Authors: Tomoki Imokawa Yoko Satoh Tomoyuki Fujioka Kanae Takahashi Mio Mori Kazunori Kubota Hiroshi Onishi Ukihide Tateishi Source Type: research
Deep learning model with collage images for the segmentation of dedicated breast positron emission tomography images
CONCLUSIONS: Deep learning can be applied for the automatic segmentation of dbPET, and collage images can improve model performance.PMID:37634221 | DOI:10.1007/s12282-023-01492-z (Source: Breast Cancer)
Source: Breast Cancer - August 27, 2023 Category: Cancer & Oncology Authors: Tomoki Imokawa Yoko Satoh Tomoyuki Fujioka Kanae Takahashi Mio Mori Kazunori Kubota Hiroshi Onishi Ukihide Tateishi Source Type: research
Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
CONCLUSION: Ex vivo gene-transduced adipocytes might be useful for cell-based gene therapy. This system may be a platform for various antibody therapies.PMID:37612442 | DOI:10.1007/s12282-023-01497-8 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Ryotaro Teranaka Hiroshi Fujimoto Takahito Masuda Masayuki Kuroda Yasuyuki Aoyagi Takeshi Nagashima Mamoru Takada Junta Sakakibara Hideyuki Yamada Hiroto Yamamoto Yoshitaka Kubota Masayuki Ohtsuka Source Type: research
Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
CONCLUSIONS: NG was useful for stratifying the risk of recurrence in patients with HR-positive, HER2-negative, node-positive EBC and was the appropriate risk assessment for patient groups not considered high-risk by HG classification.PMID:37612443 | DOI:10.1007/s12282-023-01500-2 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Takeshi Murata Masayuki Yoshida Sho Shiino Chikashi Watase Ayumi Ogawa Shohei Shikata Hiromi Hashiguchi Yukiko Yoshii Hirokazu Sugino Kenjiro Jimbo Akiko Maeshima Eriko Iwamoto Shin Takayama Akihiko Suto Source Type: research
Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
CONCLUSION: Ex vivo gene-transduced adipocytes might be useful for cell-based gene therapy. This system may be a platform for various antibody therapies.PMID:37612442 | DOI:10.1007/s12282-023-01497-8 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Ryotaro Teranaka Hiroshi Fujimoto Takahito Masuda Masayuki Kuroda Yasuyuki Aoyagi Takeshi Nagashima Mamoru Takada Junta Sakakibara Hideyuki Yamada Hiroto Yamamoto Yoshitaka Kubota Masayuki Ohtsuka Source Type: research
Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
CONCLUSIONS: NG was useful for stratifying the risk of recurrence in patients with HR-positive, HER2-negative, node-positive EBC and was the appropriate risk assessment for patient groups not considered high-risk by HG classification.PMID:37612443 | DOI:10.1007/s12282-023-01500-2 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Takeshi Murata Masayuki Yoshida Sho Shiino Chikashi Watase Ayumi Ogawa Shohei Shikata Hiromi Hashiguchi Yukiko Yoshii Hirokazu Sugino Kenjiro Jimbo Akiko Maeshima Eriko Iwamoto Shin Takayama Akihiko Suto Source Type: research
Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
CONCLUSION: Ex vivo gene-transduced adipocytes might be useful for cell-based gene therapy. This system may be a platform for various antibody therapies.PMID:37612442 | DOI:10.1007/s12282-023-01497-8 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Ryotaro Teranaka Hiroshi Fujimoto Takahito Masuda Masayuki Kuroda Yasuyuki Aoyagi Takeshi Nagashima Mamoru Takada Junta Sakakibara Hideyuki Yamada Hiroto Yamamoto Yoshitaka Kubota Masayuki Ohtsuka Source Type: research
Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
CONCLUSIONS: NG was useful for stratifying the risk of recurrence in patients with HR-positive, HER2-negative, node-positive EBC and was the appropriate risk assessment for patient groups not considered high-risk by HG classification.PMID:37612443 | DOI:10.1007/s12282-023-01500-2 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Takeshi Murata Masayuki Yoshida Sho Shiino Chikashi Watase Ayumi Ogawa Shohei Shikata Hiromi Hashiguchi Yukiko Yoshii Hirokazu Sugino Kenjiro Jimbo Akiko Maeshima Eriko Iwamoto Shin Takayama Akihiko Suto Source Type: research
Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
CONCLUSION: Ex vivo gene-transduced adipocytes might be useful for cell-based gene therapy. This system may be a platform for various antibody therapies.PMID:37612442 | DOI:10.1007/s12282-023-01497-8 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Ryotaro Teranaka Hiroshi Fujimoto Takahito Masuda Masayuki Kuroda Yasuyuki Aoyagi Takeshi Nagashima Mamoru Takada Junta Sakakibara Hideyuki Yamada Hiroto Yamamoto Yoshitaka Kubota Masayuki Ohtsuka Source Type: research
Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
CONCLUSIONS: NG was useful for stratifying the risk of recurrence in patients with HR-positive, HER2-negative, node-positive EBC and was the appropriate risk assessment for patient groups not considered high-risk by HG classification.PMID:37612443 | DOI:10.1007/s12282-023-01500-2 (Source: Breast Cancer)
Source: Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Takeshi Murata Masayuki Yoshida Sho Shiino Chikashi Watase Ayumi Ogawa Shohei Shikata Hiromi Hashiguchi Yukiko Yoshii Hirokazu Sugino Kenjiro Jimbo Akiko Maeshima Eriko Iwamoto Shin Takayama Akihiko Suto Source Type: research
Reply to "Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?"
Breast Cancer. 2023 Aug 21. doi: 10.1007/s12282-023-01495-w. Online ahead of print.NO ABSTRACTPMID:37603254 | DOI:10.1007/s12282-023-01495-w (Source: Breast Cancer)
Source: Breast Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Shozo Ohsumi Source Type: research
Reply to "Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?"
Breast Cancer. 2023 Aug 21. doi: 10.1007/s12282-023-01495-w. Online ahead of print.NO ABSTRACTPMID:37603254 | DOI:10.1007/s12282-023-01495-w (Source: Breast Cancer)
Source: Breast Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Shozo Ohsumi Source Type: research
Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data
CONCLUSIONS: At 24 months after MAS, breast cancer patients' QoL improved compared with BCS, although impairments in QoL were reported immediately after MAS. A growing expertise in surgical procedures as well as supportive care is critical to optimizing patients' well-being. These findings may be considered when counseling breast cancer patients pre- and post-surgery.TRIAL REGISTRATION NUMBER: DRKS00013335 on 27/11/2017 retrospectively registered.PMID:37587322 | DOI:10.1007/s12282-023-01494-x (Source: Breast Cancer)
Source: Breast Cancer - August 16, 2023 Category: Cancer & Oncology Authors: Shiao Li Oei Anja Thronicke Gerrit Grieb Friedemann Schad Jessica Gro ß Source Type: research
Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data
CONCLUSIONS: At 24 months after MAS, breast cancer patients' QoL improved compared with BCS, although impairments in QoL were reported immediately after MAS. A growing expertise in surgical procedures as well as supportive care is critical to optimizing patients' well-being. These findings may be considered when counseling breast cancer patients pre- and post-surgery.TRIAL REGISTRATION NUMBER: DRKS00013335 on 27/11/2017 retrospectively registered.PMID:37587322 | DOI:10.1007/s12282-023-01494-x (Source: Breast Cancer)
Source: Breast Cancer - August 16, 2023 Category: Cancer & Oncology Authors: Shiao Li Oei Anja Thronicke Gerrit Grieb Friedemann Schad Jessica Gro ß Source Type: research
Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data
CONCLUSIONS: At 24 months after MAS, breast cancer patients' QoL improved compared with BCS, although impairments in QoL were reported immediately after MAS. A growing expertise in surgical procedures as well as supportive care is critical to optimizing patients' well-being. These findings may be considered when counseling breast cancer patients pre- and post-surgery.TRIAL REGISTRATION NUMBER: DRKS00013335 on 27/11/2017 retrospectively registered.PMID:37587322 | DOI:10.1007/s12282-023-01494-x (Source: Breast Cancer)
Source: Breast Cancer - August 16, 2023 Category: Cancer & Oncology Authors: Shiao Li Oei Anja Thronicke Gerrit Grieb Friedemann Schad Jessica Gro ß Source Type: research
